Want to Buy a Semaglutide Tablet? Here's the Legal Route in the UK

The biggest myth first: you can't just add it to a basket and check out

The most common misconception is that buying a semaglutide tablet works like buying a vitamin. It doesn't, and that's not a bureaucratic inconvenience, it's a patient-safety protection that matters. Wegovy tablets are a prescription-only medicine under UK law, which means no pharmacy, online or otherwise, may legally supply them without a valid prescription issued following a clinical assessment. If you find a seller who will post them to you without that step, that is not a shortcut; it is an illegal supply and potentially a serious health risk.

The MHRA has been explicit about this. Fake and unlicensed weight-loss medicines sold online without clinical oversight have caused real harm, and enforcement teams seized around 20 million doses of illegally traded weight-loss medicines (roughly £45 million worth) in 2025 alone. When something goes wrong with an unlicensed product, there is no prescriber, no pharmacy, no one accountable. Understanding where semaglutide tablets are genuinely available starts with understanding why the prescription step is there.

A question our prescribers hear most weeks: "Can I just transfer from my current injections to the tablet without seeing anyone?" The honest answer is no, switching formulations still requires a fresh clinical review, because the dosing schedule, administration method and absorption profile are different from the weekly injection.

The legal route, from first click to delivered pen

Through a regulated private pharmacy like ours, the process has four clear stages. First, you complete a free online consultation, medical history, current medications, weight, relevant conditions. Second, a GPhC-registered Independent Prescriber reads your answers personally and makes a clinical decision. If you are suitable, a prescription is issued; if not, you get a clear explanation of why. Third, our GPhC-registered pharmacy dispenses your treatment. Fourth, DPD delivers it to your door the next working day, tracked and in plain packaging.

The clinical assessment matters because semaglutide tablets interact with other medicines, are not suitable during pregnancy or breastfeeding, and are not licensed for anyone under 18. A prescriber also checks that the BMI and health-condition criteria are met before approval, the eligibility picture for online access is slightly different from NHS criteria and is worth understanding before you start. None of this takes days. Submit before noon on a working day and, if clinically suitable, your treatment can be on its way the same afternoon.

You can verify any online pharmacy through the GPhC's public register at pharmacyregulation.org/registers. Our own premises registration number is 9012878, verifiable directly at that link. If a pharmacy cannot point you to its GPhC registration, stop there.

Who the tablet is licensed for, and what the assessment checks

Wegovy tablets were approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. The licensed criteria are adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not guarantee a prescription; the prescriber reviews the complete clinical picture.

The tablet is not the right choice for everyone. People with a history of certain conditions (including pancreatitis or medullary thyroid carcinoma) will need a careful conversation with a prescriber first. Those who are pregnant, trying to conceive, or breastfeeding are advised against it. The MHRA also notes that GLP-1 medicines are not assessed for cosmetic or purely aesthetic weight loss, as the GOV.UK guidance on GLP-1 medicines sets out clearly. Our prescribers apply exactly that standard during every review.

Trial evidence from the OASIS 4 phase-3 study (cited in the MHRA's approval announcement of 11 June 2026) reported an average weight loss of around 13.6% over 64 weeks versus 2.4% with placebo, alongside lifestyle changes. Among participants who stayed fully adherent, the figure was closer to 17%. These are the verified figures; anything substantially higher on a seller's website deserves scepticism. Exploring your weight-loss treatment options is a sensible next step if you want to compare how this sits alongside the injectable alternatives.

What to look for, and what should put you off

Legitimate supply of semaglutide tablets in the UK looks like this: a registered pharmacy, a prescriber who reviews your case, ID verification, and a clear process. It does not involve a discount code, a social-media seller, or a price that seems too far below what other regulated services charge. The MHRA has specifically warned about fake weight-loss products being sold through unregulated online channels; you can report a suspect seller directly to the MHRA via the Yellow Card scheme.

nume's commercial position is straightforward: we are not the cheapest option you will find online, and we are fine with that. One price covers the consultation, the prescription, the medicine and next-working-day delivery. There are no subscriptions, no auto-renewals, and no repeat order dispatched without another clinical review. If you have questions before starting, our FAQs cover the most common ones, and our team is available seven days a week for aftercare. More about who we are is on our about page if you want to check our credentials first.

If your GP has already suggested semaglutide on the NHS, it is worth reading about how NHS access to semaglutide tablets works, the criteria and timelines differ from the private route, and knowing both helps you make an informed decision. If you are ready to move forward through a regulated private service, you can buy semaglutide tablets here, or if you would prefer a capsule format, find out more about how to buy semaglutide pills through a clinically supervised pathway.